"Insulin Glargine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.
| Descriptor ID |
D000069036
|
| MeSH Number(s) |
D06.472.699.587.200.300.100 D12.644.548.586.200.300.100
|
| Concept/Terms |
Insulin Glargine- Insulin Glargine
- Glargine, Insulin
- A21-Gly-B31-Arg-B32-Arg-insulin
- A21 Gly B31 Arg B32 Arg insulin
- Insulin, Glycyl(A21)-Arginyl(B31,B32)
- Glargine
- Insulin, Gly(A21)-Arg(B31,B32)
Lantus- Lantus
- Lantus Solostar
- Solostar, Lantus
HOE 901- HOE 901
- 901, HOE
- HOE-901
- HOE901
|
Below are MeSH descriptors whose meaning is more general than "Insulin Glargine".
Below are MeSH descriptors whose meaning is more specific than "Insulin Glargine".
This graph shows the total number of publications written about "Insulin Glargine" by people in this website by year, and whether "Insulin Glargine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin Glargine" by people in Profiles.
-
Davies MJ, Rosenstock J, Ali A, Russell-Jones D, Souhami E, Palmer K, Ji C, Niemoeller E, Skolnik N. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin =8%, =64?mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. Diabetes Obes Metab. 2022 01; 24(1):34-41.
-
Skolnik N, Del Prato S, Blonde L, Galstyan G, Rosenstock J. Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. Adv Ther. 2021 04; 38(4):1715-1731.
-
Umpierrez GE, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C. When basal insulin is not enough: response to M Davidson. Diabetes Obes Metab. 2020 04; 22(4):711-712.
-
Legg KM, Labay LM, Aiken SS, Logan BK. Validation of a Fully Automated Immunoaffinity Workflow for the Detection and Quantification of Insulin Analogs by LC-MS-MS in Postmortem Vitreous Humor. J Anal Toxicol. 2019 Aug 23; 43(7):505-511.
-
Umpierrez GE, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C. When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control. Diabetes Obes Metab. 2019 06; 21(6):1305-1310.
-
Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
-
Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study. Adv Ther. 2018 01; 35(1):43-55.
-
Skolnik N, Dupree RS, Johnson EL. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Curr Med Res Opin. 2017 12; 33(12):2187-2194.
-
Starkman H, Frydman E, Bustami R. Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control. J Pediatr Endocrinol Metab. 2011; 24(5-6):369-71.